Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 200 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intraocular Melanoma Clear all
Terminated Phase 1Phase 2 Interventional Results available

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

NCT02743611
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma
Interventions
BPX-701, Rimiducid
Biological · Drug
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Denver, Colorado • Portland, Oregon • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 1 Interventional

Dendritic Cell Vaccination During Lymphoid Reconstruction

NCT00313508
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
Autologous Dendritic Cells (DC), Fludarabine, Autologous Lymphocyte Infusion (ALI)
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2014 · Synced Oct 20, 2026, 4:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

NCT03947385
View directory record Official record
Conditions
Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
Interventions
IDE196, Binimetinib, Crizotinib
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 20, 2026, 4:03 AM EDT
Recruiting Phase 2 Interventional

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

NCT06627244
View directory record Official record
Conditions
Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver
Interventions
Tebentafusp, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 20, 2026, 4:03 AM EDT
Completed No phase listed Observational

Cytogenetic Study of Ocular Melanoma

NCT00344799
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
Not listed
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 20, 2026, 4:03 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

NCT04130516
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody
Drug · Biological
Lead sponsor
Linnaeus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 20, 2026, 4:03 AM EDT
Terminated Not applicable Interventional Results available

Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases

NCT02336763
View directory record Official record
Conditions
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Stage IIA Uveal Melanoma, Stage IIB Uveal Melanoma, Stage IIIA Uveal Melanoma, Stage IIIB Uveal Melanoma, Stage IIIC Uveal Melanoma
Interventions
External Beam Radiation Therapy, Laboratory Biomarker Analysis
Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

NCT01430416
View directory record Official record
Conditions
Uveal Melanoma
Interventions
AEB071
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 20, 2026, 4:03 AM EDT
Terminated Phase 2 Interventional Results available

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

NCT01533948
View directory record Official record
Conditions
Extraocular Extension Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIA Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIB Melanoma, Stage IIIC Intraocular Melanoma, Stage IIIC Melanoma, Stage IV Intraocular Melanoma, Stage IV Melanoma
Interventions
axitinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 20, 2026, 4:03 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma

NCT03712904
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Stereotactic Body Radiation Therapy, Ziv-Aflibercept
Radiation · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 20, 2026, 4:03 AM EDT
Terminated Phase 1 Interventional Results available

KZR-261 in Subjects With Advanced Solid Malignancies

NCT05047536
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumor
Interventions
KZR-261
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 20, 2026, 4:03 AM EDT
Not listed No phase listed Observational

BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma

NCT01925599
View directory record Official record
Conditions
Choroidal Nevi, Uveal Melanoma
Interventions
Not listed
Lead sponsor
Amy C Schefler, MD
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

NCT00506142
View directory record Official record
Conditions
Metastatic Malignant Uveal Melanoma
Interventions
Marqibo® (vincristine sulfate liposomes injection)
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Denver, Colorado • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 20, 2026, 4:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

Tebentafusp-tebn With LDT in Metastatic UM

NCT06626516
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

NCT00680225
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
Ranibizumab injection and TTT - ICG based
Drug
Lead sponsor
New England Retina Associates
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Hamden, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 20, 2026, 4:03 AM EDT
Active, not recruiting Phase 2 Interventional

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

NCT01587352
View directory record Official record
Conditions
Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Vorinostat
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
3
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

NCT02570308
View directory record Official record
Conditions
Uveal Melanoma
Interventions
IMCgp100
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

A Study of SEA-CD40 Given With Other Drugs in Cancers

NCT04993677
View directory record Official record
Conditions
Melanoma, Carcinoma, Non-Small- Cell Lung
Interventions
SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, carboplatin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
23
States / cities
Springdale, Arkansas • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 1 Interventional Results available

Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma

NCT02771340
View directory record Official record
Conditions
Uveal Melanoma, Choroid Neoplasm
Interventions
ICON-1
Biological
Lead sponsor
Iconic Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Leawood, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 20, 2026, 4:03 AM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma

NCT00482911
View directory record Official record
Conditions
Intraocular Melanoma, Malignant Conjunctival Neoplasm
Interventions
cyclophosphamide, lenalidomide, sunitinib malate
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

NCT02858869
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage IV Non-Small Cell Lung Cancer, Stage IV Skin Melanoma, Melanoma of Unknown Primary
Interventions
Pembrolizumab, Stereotactic Radiosurgery
Biological · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Not applicable Interventional

Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma

NCT01460810
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
1000CsK Silicon Oil Tamponade
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 2 Interventional

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

NCT04417530
View directory record Official record
Conditions
Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
Interventions
AU-011, Suprachoroidal Microinjector, PDT Laser
Drug · Device
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 20, 2026, 4:03 AM EDT
Completed No phase listed Observational

Clinical and Histopathologic Characteristics of BAP1 Mutations

NCT01773655
View directory record Official record
Conditions
Malignant Pleural Mesothelioma (MPM), Choroidal Nevus, Primary Uveal Melanoma (UM), Metastatic Uveal Melanoma (UM), Renal Cell Carcinoma, Cholangiocarcinoma
Interventions
tumor specimens
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 20, 2026, 4:03 AM EDT